Home
Degron Therapeutics

Degron Therapeutics Market Share Analysis for May 2026

degron therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (mgd) drugs. degron has assembled a team of world-class executives and scientific leaders, bringing its scientific excellence to the identification and validation of disease targets, particularly those undruggable by conventional small molecule inhibitors, and novel selective mgd compounds to meet unmet medical needs in all therapeutic areas.

Industry: N/A

Domaindegrontx.com

Year Founded2021

Employees51 - 200

Annual Revenue$1M - $2M

Degron Therapeutics

Degron Therapeutics (including company regionals)

degrontx.com

See more website traffic and engagement information

Degron Therapeutics Revenue up to May 2026 is 1M - 2M

revenue generated by Degron Therapeutics top domains

Degron Therapeutics top domains revenue over 3 years

Revenue for Degron Therapeutics top domains

degrontx.com1M - 2M

See more with Sales Intelligence

Total visits to Degron Therapeutics's top domains

Understand Degron Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

degrontx.com1.8K

See more with Sales Intelligence

Avg. visit duration in Degron Therapeutics's top domains

Analyze Degron Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

degrontx.com00:01:00

See more with Sales Intelligence

Avg. pageviews on Degron Therapeutics's top domains

See how Degron Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

degrontx.com2.05

See more with Sales Intelligence

Degron Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Degron Therapeutics

These are the website technologies, by industry, used by Degron Therapeutics top domains

Advertising (2)

Baidu Ads

Audio Video Media (1)

Flowplayer

Content Management System (1)

Wix

Mobile (1)

Meta Viewport

More Technologies

2

See all

News & Signals from Degron Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMerck partners with Degrontx.Merck partners with China's Degron, Medimscience on molecular glue, autoimmune programs.

NewsDegrontx is developing molecular glues for undisclosed immune-mediated conditions on Sep 1st '25.Still, Shanghai-based Degron will go up against a giant in the immunology arena, with Novartis in September 2025 inking a $5.7 billion agreement with Monte Rosa Therapeutics to develop molecular glues for undisclosed immune-mediated conditions.

NewsDegrontx receives financing of $40M in Series A1.Degron Therapeutics has secured a $40 million Series A extension as investor interest continues building around targeted protein degradation technologies and next-generation cancer therapies aimed at previously "undruggable" disease targets.